Recent Updates
Recently added Catalysts
ACRS Positive Sentiment Score: 70/100

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Thursday, June 6, 2024 1 min read
Key Takeaway: Aclaris Therapeutics announced that Dr. Neal Walker, the Interim President & CEO, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for June 11, 2024, in Miami, Florida. A webcast of the discussion will be available on the company's website for at least 30 days following the event. Aclaris continues to pursue the development of innovative treatments for immuno-inflammatory diseases through its clinical-stage pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aclaris is actively participating in a prominent healthcare conference.
  • The company is focused on developing novel drug candidates for unmet needs.
  • Aclaris has a robust R&D pipeline targeting immuno-inflammatory diseases.

Full Press Release Details

WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida.
A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Therapeutics Contact:
investors@aclaristx.com

Frequently Asked Questions

When is Aclaris Therapeutics' fireside chat scheduled?

The fireside chat is on June 11, 2024, at 11:20 AM ET.

Who will represent Aclaris at the Goldman Sachs conference?

Dr. Neal Walker, Interim President & CEO, will represent Aclaris.

How can I access the fireside chat webcast?

The webcast can be accessed on Aclaris’ 'Events' page of their website.

What is Aclaris Therapeutics focused on developing?

Aclaris focuses on novel drug candidates for immuno-inflammatory diseases.

How long will the webcast be archived on Aclaris' site?

The webcast will be archived for at least 30 days.

Tags: ACRS Viatris Investor Conferences Healthcare Aclaris Therapeutics Goldman Sachs healthcare conference immuno-inflammatory diseases
Last updated: Jun 6, 2024